A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Advanced Malignancies, Metastatic Cancer

In brief

This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts. Part 1 is dose escalation and safety expansion which determines the optimal dose and maximum number of tolerated doses. Part 2 is dose expansion in which Part 1 recommended dose will be evaluated.

Key facts

Study ID

NCT02697591

Run by

Incyte Biosciences International Sàrl

People needed

100

Starts

2016-06-20

Expected to finish

2019-12-16

Last updated by the study team

2021-02-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
• Part 1: Participants with advanced or metastatic solid tumors.
• Part 2: Participants with advanced or metastatic adenocarcinoma of endometrium, melanoma, non-small cell lung cancer, and renal cell carcinoma.
• Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or participants who refuse standard treatment.
• Presence of measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

You may not qualify if…

• Laboratory and medical history parameters not within the protocol-defined range.
• Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
• Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.
• Receipt of a live vaccine within 30 days of planned start of study therapy.
• Active autoimmune disease.
• Prior treatment with any tumor necrosis factor super family agonist.
• Known active central nervous system metastases and/or carcinomatous meningitis.
• Evidence of active, non-infectious pneumonitis or history of interstitial lung disease.
• Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

Where it is running

• The Angeles Clinic and Research Institute — Los Angeles, California, United States
• Yale University — New Haven, Connecticut, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Memorial Sloan Kettering at Monmouth — Middletown, New Jersey, United States
• MSK Westchester — Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.